CommercialCoverageMedium impact
06.02.53, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy 06.02.53 regarding protein biomarkers for prostate cancer diagnosis and risk assessment has been reissued with an effective date of October 1, 2025. This is a commercial policy update that may affect coverage and billing for prostate cancer diagnostic testing involving protein biomarkers.
Action Required
By October 1, 2025: Review the complete policy document at the provided URL to understand specific coverage changes for protein biomarker testing in prostate cancer diagnosis. Update billing procedures and prior authorization requirements as specified in the full policy. Ensure urology providers are informed of any changes to covered services or documentation requirements.